Majid Moshirfar, MD
Ophthalmology · Salt Lake City, UTNPI 1700976313
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $41,387 of the $44,172 with a category attached, or 93.7%. Johnson & Johnson Surgical Vision, Inc. accounts for 84.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $13,519 and has fallen 53.6% since, to $6,270 in 2025. Among ophthalmology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $701.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$37K
- Leica Microsystems Inc.$3K
- Beaver-visitec International, Inc.$3K
- Alcon$1K
- Johnson & Johnson Vision Care, Inc.$209
- Glaukos Corporation$80
- plus $233 from 10 others
Across 127 payments — averaging $10,381 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$434K
- AbbVie$379K
- Alcon Research LLC$294K
- Rxsight Inc$103K
- Glaukos Corporation$60K
- Avedro Inc.$48K
What the payments were for
- Consulting fees$41,38794%
- Travel & lodging$1,8934%
- Food & beverage$8492%
- Entertainment$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 33 | $37,102 |
| Leica Microsystems Inc. | 1 | $2,750 |
| Beaver-visitec International, Inc. | 1 | $2,500 |
| Alcon | 12 | $1,297 |
| Johnson & Johnson Vision Care, Inc. | 1 | $209 |
| Glaukos Corporation | 3 | $80 |
| Haag-streit USA, Inc. | 1 | $42 |
| Biotissue Holdings Inc. | 2 | $38 |
| Dompe US, Inc. | 2 | $33 |
| Ocular Therapeutix, Inc. | 1 | $20 |
| Ivantis, Inc | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
| Carl Zeiss Meditec USA, Inc. | 1 | $17 |
| AbbVie | 1 | $14 |
| Tarsus Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,172 in reported general payments places this provider in the 95th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 37 | $35,706 |
| Prednisolone Acetate | 336 | $11,065 |
| Cyclosporine | 11 | $8,237 |
| MoxifloxacinMoxifloxacin Hcl | 219 | $5,915 |
| Ketorolac Tromethamine | 219 | $4,567 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $4,164 |
| Loteprednol Etabonate | 15 | $2,505 |
| Fluorometholone | 18 | $1,468 |
| Brimonidine Tartrate | 17 | $1,000 |
| Ofloxacin | 79 | $915 |
| Latanoprost | 95 | $702 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $638 |
| ErythromycinErythromycin Base | 43 | $462 |
| Timolol Maleate | 67 | $380 |
| Acyclovir | 12 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $14 | $39,87055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
- Amy LinSalt Lake City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.